Developer docs
API playgroundTry for free, no card

Search company profiles

Neuro-Sys

Full company profile

uuid000u7tj

Namestring
Neuro-Sys
Legal namestring
Neuro-Sys SAS
Websiteurl
neuro-sys.fr
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Neuro-Sys is a France-headquartered, privately-held contract research organization (CRO) founded in 2013 that delivers specialized in vitro and in vivo preclinical modeling services for neurodegenerative disease drug discovery. Its service portfolio spans disease models across central nervous system conditions (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis, central myelination), peripheral nervous system conditions (induced peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy, BBB penetrance studies). These models are delivered through an integrated multi-platform architecture that includes in vitro, in vivo, histology, electromyography (EMG), analytical chemistry, and biomolecular analysis platforms, supported by a dedicated mode-of-action research line covering pharmacological tools, siRNA studies, and biomolecular investigations.

The company's underlying technology stack combines classical preclinical wet-lab infrastructure with CORTEX AI, an AI-augmented data analysis capability launched in January 2024 intended to improve precision and throughput in mechanism-of-action studies. Operations are anchored at a 2,000 m² state-of-the-art research facility in Gardanne, France (opened September 2024, representing a 4x capacity expansion) and a North American commercial office in Cambridge, Massachusetts (established 2019), under a group structure that includes the operating entity Neuro-Sys SAS, Neuro-Sys Vivo SAS, and Neuro-Sys Inc. Approximately 80% of models delivered are bespoke/customized, 240+ studies were completed in 2024, and the team comprises 40+ specialized experts with 40% holding PhDs.

Neuro-Sys generates revenue on a project-based, quote-driven professional services model, with pricing negotiated per study and not publicly disclosed. Its go-to-market is enterprise field sales, with CEO, CSO, and VP of Business Development personally attending partnering meetings at major industry conferences (BIO, AD/PD, SfN, AAIC, ALS Drug Development Summit). Customers are segmented across large pharmaceutical companies, biotechnology companies, and academic institutions on a horizontal basis, with no named anchor customer logos disclosed in the available data. The company is privately held with no disclosed external funding rounds, was recognized as 'Best Neurodegenerative Disease CRO 2024' by Global Health Pharma, and its parent group (N6-Pharma Group) obtained French 'société à mission' status in June 2025.

Short descriptiontext

Neuro-Sys is a France-based, privately-held preclinical CRO founded in 2013 that provides advanced in vitro and in vivo neurodegenerative disease models (CNS, PNS, and rare diseases) to pharmaceutical, biotech, and academic clients globally from facilities in France and Cambridge, MA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGardanne, France
HQ citystring
Gardanne
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical drug discovery, neurodegenerative disease models, contract research services, in vivo pharmacology, in vitro neuroscience
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical CRO Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CRO Contract Research Services
TypeProfessional Services
Description

Contract research organization providing preclinical drug discovery services including in vitro and in vivo models, mode of action research, and drug development advisory services on a project basis to pharmaceutical, biotech, and academic clients.

neuro-sys.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Neuro-Sys is a research-driven Contract Research Organization (CRO) providing preclinical drug discovery services for neurodegenerative diseases. The company delivers advanced in vitro and in vivo models spanning CNS disorders (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis), PNS conditions (peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy). Services include mode of action research, biomolecular and analytical investigations, and drug development advisory, all supported by proprietary laboratory platforms and the CORTEX AI initiative for AI-powered data analysis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 240+ studies completed in 2024
+2 more records
Product overview1 text field

Neuro-Sys is a research-driven contract research organization (CRO) offering specialized preclinical services for neurodegenerative disease drug discovery. The company operates a multi-platform architecture combining in vitro and in vivo testing platforms (including histology, EMG, analytical, and biomolecular analysis capabilities) with disease-specific model portfolios spanning CNS disorders (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis), PNS conditions (peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy). The company also provides mode of action research services and has developed CORTEX AI, an AI-powered data analysis capability for neuroscientific studies. All services are delivered through an integrated drug development advisory platform.

Product and service1 record
1CNS Disease Models
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeOthersAnnounced on2024-09-01
Description

Neuro-Sys is listed as a service provider on Science Exchange platform, which connects researchers with contract research organizations for scientific studies.

Strategic tierMinorTypeOthersAnnounced on2024-09-01
Description

Neuro-Sys is a verified supplier on Scientist.com, a marketplace connecting pharma, biotech, and academic organizations with research service providers.

Strategic tierMinorTypeOthersAnnounced on2024-09-01
Description

Neuro-Sys is a member of Biocom California, a professional association serving the life science industry in California.

Strategic tierMinorTypeOthersAnnounced on2024-09-01
Description

Neuro-Sys is a member of CLSA, representing California's life sciences industry.

5Brain Awareness Week
Strategic tierMinorTypeOthersAnnounced on2024-09-01
Description

Neuro-Sys is a proud member/supporter of Brain Awareness Week, a global campaign to increase public awareness of brain research.

neuro-sys.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based preclinical CRO focused on CNS and neurodegenerative disease drug discovery using in vivo and in vitro models. Directly comparable to Neuro-Sys in therapeutic focus, model offerings, and customer base of pharma/biotech CNS programs.

TypeDirect peer
Description

Global preclinical CRO with neurodegenerative disease and CNS oncology models. Comparable in offering in vivo and in vitro disease models to pharma/biotech sponsors on a contract basis.

TypeBroad incumbent
Description

Global tier-1 CRO offering in vivo CNS models, neuropharmacology, and neurodegenerative disease services as part of a much broader portfolio. Comparable services but at vastly larger scale and broader therapeutic coverage.

TypeBroad incumbent
Description

Large global CRO/CDMO with preclinical capabilities including neuroscience services. Competes on scale and integrated discovery services but with broader therapeutic area coverage than Neuro-Sys.

TypeBroad incumbent
Description

Large German CRO with established neuroscience franchise and broad discovery-to-development capabilities. Overlaps with Neuro-Sys in CNS/neurodegenerative preclinical services but operates at significantly larger scale.

TypeDirect peer
Description

France-based CRO with significant CNS and neurology clinical/preclinical expertise. Comparable geographic roots and CNS therapeutic focus to Neuro-Sys, though with stronger clinical trial capabilities.

TypeBroad incumbent
Description

World's largest CRO with preclinical through clinical services including neuroscience capabilities. Competes for outsourced pharma R&D budgets but with vastly broader service portfolio than Neuro-Sys.

TypeBroad incumbent
Description

Tier-1 CRO with preclinical CNS and neurodegenerative capabilities alongside full clinical and central lab services. Represents an integrated alternative that Neuro-Sys's prospects may use instead of specialty CROs.

TypeDirect peer
Description

Global CRO with strong neuroscience and neurodegenerative disease preclinical capabilities including in vivo models and biomarker work. Comparable therapeutic specialization and CRO service model to Neuro-Sys.

TypeDirect peer
Description

UK-based drug discovery CRO with CNS and neurodegenerative disease expertise in preclinical model development. Comparable specialty CRO positioning and therapeutic focus to Neuro-Sys.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuro-Sys

Preclinical CRO Servicesneuro-sys.fr

Neuro-Sys is a France-based, privately-held preclinical CRO founded in 2013 that provides advanced in vitro and in vivo neurodegenerative disease models (CNS, PNS, and rare diseases) to pharmaceutical, biotech, and academic clients globally from facilities in France and Cambridge, MA.

What Neuro-Sys does

Neuro-Sys is a France-headquartered, privately-held contract research organization (CRO) founded in 2013 that delivers specialized in vitro and in vivo preclinical modeling services for neurodegenerative disease drug discovery. Its service portfolio spans disease models across central nervous system conditions (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis, central myelination), peripheral nervous system conditions (induced peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy, BBB penetrance studies). These models are delivered through an integrated multi-platform architecture that includes in vitro, in vivo, histology, electromyography (EMG), analytical chemistry, and biomolecular analysis platforms, supported by a dedicated mode-of-action research line covering pharmacological tools, siRNA studies, and biomolecular investigations.

The company's underlying technology stack combines classical preclinical wet-lab infrastructure with CORTEX AI, an AI-augmented data analysis capability launched in January 2024 intended to improve precision and throughput in mechanism-of-action studies. Operations are anchored at a 2,000 m² state-of-the-art research facility in Gardanne, France (opened September 2024, representing a 4x capacity expansion) and a North American commercial office in Cambridge, Massachusetts (established 2019), under a group structure that includes the operating entity Neuro-Sys SAS, Neuro-Sys Vivo SAS, and Neuro-Sys Inc. Approximately 80% of models delivered are bespoke/customized, 240+ studies were completed in 2024, and the team comprises 40+ specialized experts with 40% holding PhDs.

Neuro-Sys generates revenue on a project-based, quote-driven professional services model, with pricing negotiated per study and not publicly disclosed. Its go-to-market is enterprise field sales, with CEO, CSO, and VP of Business Development personally attending partnering meetings at major industry conferences (BIO, AD/PD, SfN, AAIC, ALS Drug Development Summit). Customers are segmented across large pharmaceutical companies, biotechnology companies, and academic institutions on a horizontal basis, with no named anchor customer logos disclosed in the available data. The company is privately held with no disclosed external funding rounds, was recognized as 'Best Neurodegenerative Disease CRO 2024' by Global Health Pharma, and its parent group (N6-Pharma Group) obtained French 'société à mission' status in June 2025.

Neuro-Sys firmographics

Firmographics
Name
Neuro-Sys
Legal name
Neuro-Sys SAS
Website
https://neuro-sys.fr
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Neuro-Sys is a France-based, privately-held preclinical CRO founded in 2013 that provides advanced in vitro and in vivo neurodegenerative disease models (CNS, PNS, and rare diseases) to pharmaceutical, biotech, and academic clients globally from facilities in France and Cambridge, MA.
Ownership category
akta.pro rank

Neuro-Sys industry classification

Industry
Product category
Preclinical CRO Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Preclinical drug discovery
  • Neurodegenerative disease models
  • Contract research services
  • In vivo pharmacology
  • In vitro neuroscience

Where Neuro-Sys is headquartered

Location

Headquarters

HQ city
Gardanne
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Neuro-Sys business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. CRO Contract Research Services: Contract research organization providing preclinical drug discovery services including in vitro and in vivo models, mode of action research, and drug development advisory services on a project basis to pharmaceutical, biotech, and academic clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Neuro-Sys product offering

Product offering

Core offering

Neuro-Sys is a research-driven Contract Research Organization (CRO) providing preclinical drug discovery services for neurodegenerative diseases. The company delivers advanced in vitro and in vivo models spanning CNS disorders (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis), PNS conditions (peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy). Services include mode of action research, biomolecular and analytical investigations, and drug development advisory, all supported by proprietary laboratory platforms and the CORTEX AI initiative for AI-powered data analysis.

Product overview

Neuro-Sys is a research-driven contract research organization (CRO) offering specialized preclinical services for neurodegenerative disease drug discovery. The company operates a multi-platform architecture combining in vitro and in vivo testing platforms (including histology, EMG, analytical, and biomolecular analysis capabilities) with disease-specific model portfolios spanning CNS disorders (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis), PNS conditions (peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy). The company also provides mode of action research services and has developed CORTEX AI, an AI-powered data analysis capability for neuroscientific studies. All services are delivered through an integrated drug development advisory platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • CNS Disease Models

Quantifiable outcome

  • 240+ studies completed in 2024
  • +2 more outcomes

Companies that use Neuro-Sys

Customer profile

Segments3 records

Ideal customer profiles3 records

Neuro-Sys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Neuro-Sys partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor.

  • Science ExchangeminorOthers · 1 September 2024Neuro-Sys is listed as a service provider on Science Exchange platform, which connects researchers with contract research organizations for scientific studies.
  • Scientist.comminorOthers · 1 September 2024Neuro-Sys is a verified supplier on Scientist.com, a marketplace connecting pharma, biotech, and academic organizations with research service providers.
  • Biocom CaliforniaminorOthers · 1 September 2024Neuro-Sys is a member of Biocom California, a professional association serving the life science industry in California.
  • California Life Sciences Association (CLSA)minorOthers · 1 September 2024Neuro-Sys is a member of CLSA, representing California's life sciences industry.
  • Brain Awareness WeekminorOthers · 1 September 2024Neuro-Sys is a proud member/supporter of Brain Awareness Week, a global campaign to increase public awareness of brain research.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Neuro-Sys competitors and assessment

Company assessment

Direct peers

  • PsychoGenics: US-based preclinical CRO focused on CNS and neurodegenerative disease drug discovery using in vivo and in vitro models. Directly comparable to Neuro-Sys in therapeutic focus, model offerings, and customer base of pharma/biotech CNS programs.
  • Crown Bioscience: Global preclinical CRO with neurodegenerative disease and CNS oncology models. Comparable in offering in vivo and in vitro disease models to pharma/biotech sponsors on a contract basis.
  • Biotrial (Syneirse): France-based CRO with significant CNS and neurology clinical/preclinical expertise. Comparable geographic roots and CNS therapeutic focus to Neuro-Sys, though with stronger clinical trial capabilities.
  • QPS Holdings: Global CRO with strong neuroscience and neurodegenerative disease preclinical capabilities including in vivo models and biomarker work. Comparable therapeutic specialization and CRO service model to Neuro-Sys.
  • Sygnature Discovery: UK-based drug discovery CRO with CNS and neurodegenerative disease expertise in preclinical model development. Comparable specialty CRO positioning and therapeutic focus to Neuro-Sys.

Broad incumbents

  • Charles River Laboratories: Global tier-1 CRO offering in vivo CNS models, neuropharmacology, and neurodegenerative disease services as part of a much broader portfolio. Comparable services but at vastly larger scale and broader therapeutic coverage.
  • WuXi AppTec: Large global CRO/CDMO with preclinical capabilities including neuroscience services. Competes on scale and integrated discovery services but with broader therapeutic area coverage than Neuro-Sys.
  • Evotec: Large German CRO with established neuroscience franchise and broad discovery-to-development capabilities. Overlaps with Neuro-Sys in CNS/neurodegenerative preclinical services but operates at significantly larger scale.
  • IQVIA: World's largest CRO with preclinical through clinical services including neuroscience capabilities. Competes for outsourced pharma R&D budgets but with vastly broader service portfolio than Neuro-Sys.
  • Labcorp Drug Development (formerly Covance): Tier-1 CRO with preclinical CNS and neurodegenerative capabilities alongside full clinical and central lab services. Represents an integrated alternative that Neuro-Sys's prospects may use instead of specialty CROs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Neuro-Sys social profiles

Digital presence

Neuro-Sys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuro-Sys leadership team

Management profile

Number of profiles

Neuro-Sys subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Neuro-Sys funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuro-Sys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuro-Sys

What does Neuro-Sys do?

Neuro-Sys is a research-driven Contract Research Organization (CRO) providing preclinical drug discovery services for neurodegenerative diseases. The company delivers advanced in vitro and in vivo models spanning CNS disorders (Alzheimer's, Parkinson's, ALS, stroke, Huntington's, multiple sclerosis), PNS conditions (peripheral neuropathies, nerve crush), and rare diseases (adrenoleukodystrophy, lysosomal diseases, multiple system atrophy). Services include mode of action research, biomolecular and analytical investigations, and drug development advisory, all supported by proprietary laboratory platforms and the CORTEX AI initiative for AI-powered data analysis.

Is Neuro-Sys a public or private company?

Neuro-Sys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Neuro-Sys founded?

Neuro-Sys was founded in 2013. It employs 11 to 50 people.

Where is Neuro-Sys based?

Neuro-Sys is headquartered in Gardanne, France, in the Europe region.

How does Neuro-Sys make money?

One revenue line is on record: CRO Contract Research Services.

Who are Neuro-Sys's main competitors?

Direct peers on record are PsychoGenics, Crown Bioscience, Biotrial (Syneirse), QPS Holdings and Sygnature Discovery. Broad incumbents are Charles River Laboratories, WuXi AppTec, Evotec, IQVIA and Labcorp Drug Development (formerly Covance).

Does Neuro-Sys have an API?

No public API is recorded for Neuro-Sys.

What industry is Neuro-Sys in?

Neuro-Sys's product category is Preclinical CRO Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals